title: Hologram quantitative structure-activity relationship and comparative molecular field analysis studies within a series of tricyclic phthalimide HIV-1 integrase inhibitors.
abstract: Acquired immunodeficiency syndrome is a public health problem worldwide caused by the Human immunodeficiency virus (HIV). Treatment with antiretroviral drugs is the best option for viral suppression, reducing morbidity and mortality. However, viral resistance in HIV-1 therapy has been reported. HIV-1 integrase (IN) is an essential enzyme for effective viral replication and an attractive target for the development of new inhibitors. In the study reported here, two- and three-dimensional quantitative structure-activity relationship (2D/3D-QSAR) studies, applying hologram quantitative structure-activity relationship (HQSAR) and comparative molecular field analysis (CoMFA) methods, respectively, were performed on a series of tricyclic phthalimide HIV-1 IN inhibitors. The best HQSAR model (q (2) = 0.802, r (2) = 0.972) was obtained using atoms, bonds, and connectivity as the fragment distinction, a fragment size of 2-5 atoms, hologram length of 61 bins, and six components. The best CoMFA model (q (2) = 0.748, r (2) = 0.974) was obtained with alignment of all atoms of the tricyclic phthalimide moiety (alignment II). The HQSAR contribution map identified that the carbonyl-hydroxy-aromatic nitrogen motif made a positive contribution to the activity of the compounds. Furthermore, CoMFA contour maps suggested that bulky groups in meta and para positions in the phenyl ring would increase the biological activity of this class. The conclusions of this work may lead to a better understanding of HIV-1 IN inhibition and contribute to the design of new and more potent derivatives.
authors.affiliation: Universidade Federal do Rio de Janeiro, Faculdade de Farmácia, Laboratório de Modelagem Molecular and QSAR (ModMolQSAR), Rio de Janeiro, RJ, Brazil.
authors.forename: Uiaran de Oliveira
authors.initials: Ude O
authors.lastname: Magalhães
authors.forename: Alessandra Mendonça Teles de
authors.initials: AM
authors.lastname: Souza
authors.forename: Magaly Girão
authors.initials: MG
authors.lastname: Albuquerque
authors.forename: Monique Araújo de
authors.initials: MA
authors.lastname: Brito
authors.forename: Murilo Lamim
authors.initials: ML
authors.lastname: Bello
authors.forename: Lucio Mendes
authors.initials: LM
authors.lastname: Cabral
authors.forename: Carlos Rangel
authors.initials: CR
authors.lastname: Rodrigues
mesh_terms: D015195:Drug Design; D024882:Drug Resistance, Viral; D019428:HIV Integrase Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects; D006696:Holography / Q000379:methods*; D006801:Humans; D008958:Models, Molecular; D058990:Molecular Targeted Therapy; D010797:Phthalimides / Q000737:chemistry / Q000494:pharmacology*; D021281:Quantitative Structure-Activity Relationship
chemical_list: D019428:HIV Integrase Inhibitors; D010797:Phthalimides
keywords: 2D/3D-QSAR; 3D-QSAR; AIDS; CoMFA; HQSAR
references.citation: Bioorg Med Chem Lett. 2010 Jun 1;20(11):3254-8
references.pmid: 20452769
references.citation: J Am Chem Soc. 1988 Aug 1;110(18):5959-67
references.pmid: 22148765
references.citation: Curr Opin Infect Dis. 2013 Feb;26(1):43-9
references.pmid: 23242340
references.citation: Nat Rev Drug Discov. 2013 Feb;12(2):87-90
references.pmid: 23370234
references.citation: Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2251-6
references.pmid: 22308350
references.citation: Curr Opin HIV AIDS. 2012 Sep;7(5):401-8
references.pmid: 22789986
references.citation: Molecules. 2012 Jun 25;17(7):7666-94
references.pmid: 22732882
references.citation: J Med Chem. 2005 Mar 24;48(6):1930-40
references.pmid: 15771437
references.citation: Ann N Y Acad Sci. 2011 Mar;1222:83-9
references.pmid: 21434946
references.citation: J Mol Graph Model. 2002 Jan;20(4):269-76
references.pmid: 11858635
references.citation: Bioorg Med Chem Lett. 2002 Jun 3;12(11):1537-41
references.pmid: 12031337
references.citation: Retrovirology. 2012 Oct 04;9:82
references.pmid: 23035819
references.citation: Molecules. 2012 Aug 09;17(8):9529-39
references.pmid: 22878227
references.citation: Drug Resist Updat. 2010 Aug-Oct;13(4-5):139-50
references.pmid: 20570551
references.citation: Bioorg Med Chem. 2006 Dec 15;14(24):8420-9
references.pmid: 17005407
references.citation: Nat Rev Drug Discov. 2005 Mar;4(3):236-48
references.pmid: 15729361